Bioceres Crop Solutions' (NASDAQ:BIOX) Weak Earnings May Only Reveal A Part Of The Whole Picture

Last week's earnings announcement from Bioceres Crop Solutions Corp. (NASDAQ:BIOX) was disappointing to investors, with a sluggish profit figure. We did some further digging and think they have a few more reasons to be concerned beyond the statutory profit.

See our latest analysis for Bioceres Crop Solutions

earnings-and-revenue-history
NasdaqGS:BIOX Earnings and Revenue History March 7th 2025
Advertisement

An Unusual Tax Situation

We can see that Bioceres Crop Solutions received a tax benefit of US$6.4m. This is of course a bit out of the ordinary, given it is more common for companies to be paying tax than receiving tax benefits! We're sure the company was pleased with its tax benefit. However, our data indicates that tax benefits can temporarily boost statutory profit in the year it is booked, but subsequently profit may fall back. In the likely event the tax benefit is not repeated, we'd expect to see its statutory profit levels drop, at least in the absence of strong growth. So while we think it's great to receive a tax benefit, it does tend to imply an increased risk that the statutory profit overstates the sustainable earnings power of the business.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Bioceres Crop Solutions' Profit Performance

As we have already discussed Bioceres Crop Solutions reported that it received a tax benefit, rather than paying tax, in the last year. As a result we don't think its profit result, which includes that tax-boost, is a good guide to its sustainable profit levels. Because of this, we think that it may be that Bioceres Crop Solutions' statutory profits are better than its underlying earnings power. In further bad news, its earnings per share decreased in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. Our analysis shows 3 warning signs for Bioceres Crop Solutions (1 is significant!) and we strongly recommend you look at them before investing.

This note has only looked at a single factor that sheds light on the nature of Bioceres Crop Solutions' profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Valuation is complex, but we're here to simplify it.

Discover if Bioceres Crop Solutions might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

MI
mitchell_lawler
mitchell_lawler

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap.

Moderna nearly tripled overnight, and every other mRNA stock jumped with it. I think that could be a trap. cover
78
PR
pri_dlp7z

Happy for the melanoma patients. It is no surprise that other companies moved up too. It's the optionality getting priced in.

QU
Quantanium

There’s a 60% to 85% probability of the vaccine being approved based on historical drug development data. Could be a lot of scrutiny by the FDA due to the novel platform used.

Market might be getting a little ahead of itself here.

About NasdaqGS:BIOX

Bioceres Crop Solutions

Develops and commercializes crop productivity solutions.

Good value with imperfect balance sheet.

Advertisement

Weekly Picks

RI
Rick_Orford
FJET logo
Rick_Orford on Starfighters Space ·

The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market

Fair Value:US$520.6% undervalued
53 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
JO
John_Eric
MELI logo
John_Eric on MercadoLibre ·

MercadoLibre and the Spreadsheet Trick That Decides Everything

Fair Value:US$7.31k73.9% undervalued
97 users have followed this narrative
2 users have commented on this narrative
14 users have liked this narrative
RC
PYPL logo
rcb9 on PayPal Holdings ·

Ten Percent More Volume, One Percent More Transaction Margin

Fair Value:US$70.8913.6% undervalued
12 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
HE
HedgeY
MU logo
HedgeY on Micron Technology ·

Micron - The Memory Bottleneck Behind the AI Supercycle

Fair Value:US$1.25k25.0% undervalued
35 users have followed this narrative
0 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

AS
AstrisCorporateAdvisory
9436 logo
AstrisCorporateAdvisory on Okinawa Cellular Telephone ·

Mobile strategy pays off as churn falls

Fair Value:JP¥3.26k23.3% overvalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AS
AstrisCorporateAdvisory
3636 logo
AstrisCorporateAdvisory on Mitsubishi Research Institute ·

Exceptionally strong Q1 results, while FY guidance intact

Fair Value:JP¥4.2k18.8% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
ANTONI0
IEL logo
ANTONI0 on IDP Education ·

IDP Education Limited (ASX: IEL) - A contrarian Review

Fair Value:AU$4.6563.0% undervalued
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
330 users have followed this narrative
9 users have commented on this narrative
16 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9115.3% overvalued
184 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
KI
AMZN logo
KiwiInvest on Amazon.com ·

Amazon's high growth, high tech segments propel its profits, while traditional segments plod along

Fair Value:US$475.0944.0% undervalued
209 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative